Kristin Ladell

Kristin Ladell

Auto-generated profile, based on publicly available information

Kristin Ladell

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MSMikhail Shugay
Mikhail Shugay
DBDmitriy V Bagaev
Dmitriy V Bagaev
IZIvan V Zvyagin
Ivan V Zvyagin
RVRenske M Vroomans
Renske M Vroomans
JCJeremy Chase Crawford
Jeremy Chase Crawford
DCDmitriy M Chudakov
Dmitriy M Chudakov
The ability to decode antigen specificities encapsulated in the sequences of rearranged T-cell receptor (TCR) genes is critical for our understanding of the adaptive immune system and promises significant advances in the field of translational medicine. Recent developments in high-throughput sequencing methods (immune repertoire sequencing technology, or RepSeq) and single-cell RNA sequencing technology have allowed us to obtain huge numbers of TCR sequences from donor samples and link them to T-cell phenotypes. However, our ability to annotate these TCR sequences still lags behind, owing to the enormous diversity of the TCR repertoire and the scarcity of available data on T-cell specificities. In this paper, we present VDJdb, a database that stores and aggregates the results of published T-cell specificity assays and provides a universal platform that couples antigen specificities with TCR sequences. We demonstrate that VDJdb is a versatile instrument for the annotation of TCR repertoire data, enabling a concatenated view of antigen-specific TCR sequence motifs. VDJdb can be accessed at https://vdjdb.cdr3.net and https://github.com/antigenomics/vdjdb-db.

14 July 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
VTViggo Van Tendeloo
Viggo Van Tendeloo
AVAnn Van de Velde
Ann Van de Velde
ADAnn Van Driessche
Ann Van Driessche
NCNathalie Cools
Nathalie Cools
SASébastien Anguille
Sébastien Anguille
ZBZwi N. Berneman
Zwi N. Berneman
Active immunization using tumor antigen-loaded dendritic cells holds promise for the adjuvant treatment of cancer to eradicate or control residual disease, but so far, most dendritic cell trials have been performed in end-stage cancer patients with high tumor loads. Here, in a phase I/II trial, we investigated the effect of autologous dendritic cell vaccination in 10 patients with acute myeloid leukemia (AML). The Wilms’ tumor 1 protein (WT1), a nearly universal tumor antigen, was chosen as an immunotherapeutic target because of its established role in leukemogenesis and superior immunogenic characteristics. Two patients in partial remission after chemotherapy were brought into complete remission after intradermal administration of full-length WT1 mRNA-electroporated dendritic cells. In these two patients and three other patients who were in complete remission, the AML-associated tumor marker returned to normal after dendritic cell vaccination, compatible with the induction of molecular remission. Clinical responses were correlated with vaccine-associated increases in WT1-specific CD8 + T cell frequencies, as detected by peptide/HLA-A*0201 tetramer staining, and elevated levels of activated natural killer cells postvaccination. Furthermore, vaccinated patients showed increased levels of WT1-specific IFN-γ–producing CD8 + T cells and features of general immune activation. These data support the further development of vaccination with WT1 mRNA-loaded dendritic cells as a postremission treatment to prevent full relapse in AML patients.

1 March 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
MDMartin Davey
Martin Davey
CWCarrie R. Willcox
Carrie R. Willcox
SJStephen P. Joyce
Stephen P. Joyce
KLKristin Ladell
Kristin Ladell
SKSofya A. Kasatskaya
Sofya A. Kasatskaya
BWBenjamin E. Willcox
Benjamin E. Willcox
γδ T cells are considered to be innate-like lymphocytes that respond rapidly to stress without clonal selection and differentiation. Here we use next-generation sequencing to probe how this paradigm relates to human Vδ2negT cells, implicated in responses to viral infection and cancer. The prevalent Vδ1 T cell receptor (TCR) repertoire is private and initially unfocused in cord blood, typically becoming strongly focused on a few high-frequency clonotypes by adulthood. Clonal expansions have differentiated from a naive to effector phenotype associated with CD27 downregulation, retaining proliferative capacity and TCR sensitivity, displaying increased cytotoxic markers and altered homing capabilities, and remaining relatively stable over time. Contrastingly, Vδ2+T cells express semi-invariant TCRs, which are present at birth and shared between individuals. Human Vδ1+T cells have therefore evolved a distinct biology from the Vδ2+subset, involving a central, personalized role for the γδ TCR in directing a highly adaptive yet unconventional form of immune surveillance.

6 May 2012 in Nature Medicine
Verified
Journal Article
Closed access
NLNathaniel Liddy
Nathaniel Liddy
GBGiovanna Bossi
Giovanna Bossi
KAKatherine J Adams
Katherine J Adams
ALAnna Lissina
Anna Lissina
TMTara M Mahon
Tara M Mahon
BJBent K Jakobsen
Bent K Jakobsen

12 October 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
GGGiovanni Galletti
Giovanni Galletti
GSGabriele De Simone
Gabriele De Simone
EMEmilia M. C. Mazza
Emilia M. C. Mazza
SPSimone Puccio
Simone Puccio
CMClaudia Mezzanotte
Claudia Mezzanotte
ELEnrico Lugli
Enrico Lugli

9 February 2018 in Science Immunology
Verified
Journal Article
Closed access
PDF file
SCSlobodan Culina
Slobodan Culina
ALAna Ines Lalanne
Ana Ines Lalanne
GAGeorgia Afonso
Georgia Afonso
KCKaren Cerosaletti
Karen Cerosaletti
SPSheena Pinto
Sheena Pinto
RMRoberto Mallone
Roberto Mallone
Islet-reactive CD8 + T cells are common in the periphery, but home to the pancreas preferentially in the context of type 1 diabetes.